洞察
Insights From Our Experts
Articles
Unveiling Challenges: Analyzing Stakeholder Feedback on the EU Joint Clinical Assessment Implementation Act and Its Impact on the Latest Draft
On March 5, 2024, the draft Implementation Act (IA) for Joint Clinical Assessment (JCA) for medicinal products was released for public comments. The intent of the draft IA was to provide more granular details on the…
Transforming Systematic Literature Reviews: Leveraging AI for Efficiency and Rigor
Systematic literature reviews (SLRs) are instrumental in supporting healthcare decision-making and market access. Traditionally, literature reviews require a resource-intensive process, thus highlighting the need for more efficient methodologies without compromising rigor or integrity. Over the past…
Decoding EMA’s Blueprint on Real-World Evidence
The European Medicines Agency (EMA) has published a document that elaborates on the application of Real-World Data (RWD) in evaluating human medicines. This document succinctly outlines the utility of Real-World Evidence (RWE), which is derived from…
Predicting Telehealth Use through the Power of Machine Learning: Insights from EVERSANA to Be Shared at Upcoming PMSA Conference.
Telehealth has emerged as a vital channel for health services delivery in the post-COVID era. However, understanding patient telehealth use remains a complex challenge for healthcare providers. At EVERSANA, our experts are leveraging machine learning techniques…
Navigating Pharmaceutical Success: Harnessing Data Analytics and Predictive Modeling
In the fast-paced world of pharmaceuticals, where market forecasting and regulatory compliance are paramount, data-driven insights can make all the difference. Discover how EVERSANA’s Specialty Consulting team excels in crafting tailored predictive modeling solutions for pharmaceutical…
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs
Understanding ICER’s 2024 Protocol for Assessing Unsupported Price Increases on Prescription Drugs The Institute for Clinical and Economic Review (ICER) has recently updated its protocol for assessing unsupported price increases of prescription drugs. This initiative provides…
Sound Off on Interoperability – Leveraging Next-Gen Tech for Enhanced Electronic Benefit Verification and Prior Authorizations to Streamline Workflow
The theme of a recent panel at Access USA was “Technology: the Good, the Bad, and the Ugly.” While serving as an instrument for addressing challenges, technological progress can also introduce new complexities. Watch the recording…
Growing EVERSANA’s Value & Evidence Global Footprint with the Additions of Monique Martin, Pamela Vo and Deepika Thakur
EVERSANA’s Value and Evidence (V&E) team grew their global Health Economics & Outcomes Research (HEOR) leadership footprint in early 2024 with the addition of Monique Martin, Pamela Vo and Deepika Thakur, showcasing EVERSANA’s growing global life…
Unlocking Insights: EVERSANA’s Value & Evidence Team’s Impact on Economic and Healthcare Resource Utilization Outcomes in Robotic vs. Manual Total Knee Arthroplasty
The use of robotics in surgical procedures is becoming increasingly popular, with the potential to reshape the landscape of modern surgery. In total knee arthroplasty (TKA), the increased adoption of robotics has improved clinical outcomes, including…
Pioneering the Path: How Medical Affairs is Charting the Course for Pre- and Post-Launch Strategies
Early involvement of Medical Affairs in the product lifecycle is not just beneficial – it is mission critical. In the swiftly changing realm of advanced therapies like biosimilars, rare disease molecules, and cell and gene therapies,…